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Summary 
Polycystic Ovary Syndrome (PCOS) is a common female condition typified by reproductive, 
hyperandrogenic and metabolic features. PCOS is a genetic condition, exacerbated by 
obesity. There is a close link between obesity and PCOS based on epidemiological data, 
and more recently corroborated through genetic studies. There are many mechanisms 
mediating the effects of weight gain and obesity on the development of PCOS. The 
metabolic effects of insulin resistance and steroidogenic and reproductive effects of 
hyperinsulinaemia are important mechanisms. Adipokine production by subcutaneous and 
visceral fat appears to play a part in metabolic function. However, given the complexity of 
PCOS pathogenesis, it is important also to consider possible effects of PCOS on further 
weight gain, or at least on hampering attempts at weight loss and maintenance through 
lifestyle changes. Possible mediators of these effects include changes in energy 
expenditure, mental ill health or physical inactivity. In this brief review, we discuss the 
main mechanisms that underlie the association between obesity and PCOS, from divergent 
perspectives of weight gain contributing to development of PCOS and vice versa. We also 
consider novel management options for women with obesity and PCOS. 
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Introduction 
For billions of years, the eukaryotic cell and, more recently its multi-cellular 
manifestations have evolved to mitigate against nutrient scarcity. This, combined with 
oxygen free radicals and hypothermia, represent major threats to species survival. In 
response to these threats, our complex physiology has adapted through diverse 
mechanisms. Provision of a ready supply of nutrients through storage of energy in the liver 
and adipose tissue in times of plenty and use of alternate fuel sources such as ketone 
bodies when food is scarce, mitigates against starvation. Efficient and timely eradication 
of oxygen free radicals, generated through mitochondrial oxidative respiration through 
enzymes such as Superoxide Dismutase, mitigates against the harmful effects of oxygen 
free radicals. Maintenance of a constant body temperature, through shivering activity and 
activation of brown adipose tissue in response to cold exposure, mitigates against 
hypothermia. 
 
For the last 50 years, Homo sapiens has been navigating a white water ride. Although 
environmental turbulence is usually necessary for evolutionary change, what is unusual 
about our current ‘white water ride’ is the assumption of its cause being antipodal to a 
more familiar threat of nutrient scarcity: that of nutrient abundance. (Abundance of a 
substance essential for life is not altogether unprecedented: oxygen abundance during the 
cambrian era may have precipitated the Cambrian explosion of multicellular life). Of 
course, this perspective is almost certainly a gross over-simplification. The development 
of the global obesity epidemic over the last half century is likely to be multi-factorial and 
complex, and go far beyond simple food abundance. However, whatever its actual 
cause(s), obesity accounts for a huge component of global ill health, and is associated 
with at least 50 obesity-related co-morbidities (1-3). Global obesity also confers a 
substantial socio-economic burden. Expenditure on obesity and its numerous sequelae 
accounts for a substantial proportion of healthcare costs globally.  
Most obesity-related co-morbidities associate with cardiometabolic dysfunction. This 
includes development of conditions like Type 2 Diabetes Mellitus (T2D), Hypertension and 
other features of the metabolic syndrome. Obesity-related malignancies such as 
endometrial carcinoma also associate with underlying cardiometabolic dysfunction, insulin 
resistance and compensatory hyperinsulinaemia (4).  
Polycystic Ovary Syndrome (PCOS) is an important example of a metabolic disorder, 
associated with insulin resistance, the manifestations of which include cardiometabolic 
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risk, and the effects of which greatly amplified by obesity (2, 5, 6). Accordingly, PCOS 
associates with heightened risk for the development of T2D (7), impaired glucose 
tolerance (8), dyslipidaemia, non-alcoholic fatty liver disease (9) and obstructive sleep 
apnoea (10). PCOS has a prevalence of between 6-10% in reproductive-age women (11-14). 
Although PCOS can manifest at any stage of reproductive life, it often develops during 
adolescence (2). PCOS is typified by both reproductive and hyperandrogenic features that 
include oligo-amenorrhoea, impaired fertility, hirsutism, acne and androgenic alopecia. 
PCOS often also presents with hyperandrogenaemia (2).  
The frequent co-occurrence of obesity with PCOS, the inherent complexity of each 
condition, and the association of each with cardiometabolic dysfunction and insulin 
resistance, can make discernment of pathogenic pathways challenging. PCOS is an obesity-
related condition. As such, weight-gain and obesity contribute towards the development 
of PCOS. However, there are also mechanisms whereby the development of PCOS can 
contribute towards further weight-gain, and hamper efforts to establish effective weight-
loss. In this brief review, we explore the mechanisms whereby weight-gain and obesity 
contribute towards development of PCOS, and vice versa (summarized in figure 1). We 
also explore novel strategies for sustained weight-loss in the management of women with 
PCOS, and in its prevention.   
 
Obesity as a risk factor for the development of PCOS 
In women who are genetically predisposed to development of PCOS, weight-gain and 
obesity often result in its clinical and biochemical manifestation. Accordingly, there are 
close links between obesity and PCOS. The majority of women with PCOS (38-88%) are 
either overweight or obese (2, 15, 16). Data from the Northern Finland Birth Cohort 
(NFBC) 1966 show a significant association between BMI and features of PCOS at all ages 
(17). Furthermore, modest weight loss (around 5%) often results in clinically meaningful 
improvements in the reproductive, hyperandrogenic and metabolic features of PCOS (18, 
19). Outlined below are factors that mediate the effects of weight gain and obesity on the 
pathogenesis of PCOS. 
 
Insulin Resistance and Fat Distribution in the development of PCOS 
The majority of women with PCOS (50-90%) are insulin resistant (20-22). There is poor 
understanding of the origin of insulin resistance in PCOS and the mechanisms implicated. 
It is likely that testosterone and the CAG repeat number within the androgen receptor 
contribute towards insulin resistance in PCOS (23). In one study in PCOS, there was 
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demonstration of a post-receptor defect specific to the phosphatidylinositol 3-kinase (PI3-
kinase) pathway. This pathway is responsible for mediating the metabolic effects of insulin 
(including glucose disposal into skeletal muscle) (2). Whatever the mechanisms, insulin 
resistance underlies association of PCOS with dysmetabolic features. Insulin also mediates 
steroidogenic and cell-growth effects however, through a separate post-receptor pathway, 
the mitogen-activated protein (MAP) kinase pathway, which remains intact (2, 24). 
Compensatory hyperinsulinaemia, secondary to insulin resistance in PCOS, has stimulatory 
effects on the intact MAP kinase (and the impaired PI3-kinase) pathway to enhance 
steroidogenesis (25). Therefore, although PCOS is a condition that associates with insulin 
resistance, it is important to appreciate that this only accounts for one side of the coin. 
An equally important aspect of PCOS pathogenesis relates to the pleiotropic steroidogenic 
effects (including hyperandrogenaemia and reproductive dysfunction) of excessive insulin, 
enabled through an intact MAP kinase post-receptor insulin pathway.  
 
Compensatory hyperinsulinaemia in PCOS has multiple effects on peripheral tissues, 
including co-gonadotrophic effects within ovarian theca cells (characterized by synergism 
with luteinising hormone [LH] through activation of CYP17 [P450c17α], a key enzyme in 
androgen biosynthesis within the ovary) (26-28). It is also well established that ovulatory 
dysfunction in PCOS results from the adverse effects of hyperinsulinaemia on pre-antral 
follicular development (29, 30). Other effects of insulin in PCOS that likely contribute 
towards the development of hyperandrogenaemia in this condition include enhancement 
of LH pulse amplitude in pituitary tissue (shown in rodent models) (21, 31), and 
stimulation of adrenal P450c17α activity (32). Furthermore, insulin may also suppress 
production of sex hormone binding globulin (SHBG) within the liver (33, 34), thereby 
further enhancing androgenicity through increased levels of free (biologically available) 
testosterone.  
 
Weight gain and obesity worsens insulin resistance and features of the metabolic syndrome 
(35). Weight gain and obesity in women with PCOS also promotes worsening insulin 
resistance (2), and both metabolic dysfunction (mediated through further impairment of 
the PI3-kinase post-receptor insulin pathway), and the characteristic reproductive and 
hyperandrogenic features of this condition. Therefore, the effects of weight gain on 
insulin resistance and hyperinsulinaemia, and the dysmetabolic and steroidogenic 
implications of the impaired PI3-kinase and intact MAP kinase post-receptor insulin 
pathways respectively form a central component of PCOS pathogenesis, and underlie the 
association of weight gain and obesity with PCOS. This explanation also provides a 
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rationale for the benefits of successful weight-loss in obese and overweight women with 
PCOS, through improved insulin sensitivity and serum insulin levels and favourable impact 
on metabolic health, reproductive function (including restoration of ovulation, menstrual 
cyclicity and fertility), and hyperandrogenic features (2, 19, 36).  
 
Regarding pathogenesis of insulin resistance inherent to PCOS, it is important to consider a 
possible role for visceral fat preponderance as a contributor, given the known effects of 
visceral fat on metabolic dysfunction through adipokine and fatty acid release (37-39). 
Unfortunately, some of the earlier imaging studies in PCOS used techniques such as 
lipometer (40) and ultrasound (41), which are limited by operator-dependence (42). Dual-
energy X-ray absorptiometry (DEXA) has also been used (43, 44), although this technique 
does not allow for discernment between visceral and subcutaneous abdominal fat depots 
(42). Another limitation of some imaging studies in PCOS includes lack of an appropriately 
BMI-matched control group for comparison (42). 
 
Our own group employed MR (with highly resolved images and clear delineation of fat 
depots) in 22 obese BMI- and fat mass-matched pairs of PCOS cases and controls to 
determine cross-sectional areas of fat depots (including visceral fat) at anatomically pre-
defined sites (45). We demonstrated that fat depots including visceral fat, are equivalent 
between women with PCOS and control women (45), despite significant differences in 
insulin resistant between the two groups. Subsequent MR-based studies in women with 
PCOS versus control women show similar findings (46, 47). Based on these more recent 
imaging studies using a gold standard approach of MR-based methodology, it seems that 
women with PCOS manifest global adiposity, rather than a preponderance of visceral fat 
(45). However, visceral fat may still be important in PCOS as a contributor towards insulin 
resistance. There is a positive correlation between total body fat mass and visceral fat 
mass in women regardless of PCOS status (42, 45, 48). Changes in body weight in women 
with PCOS would therefore influence visceral fat content and metabolic risk. The role of 
ectopic fat as a mediator of metabolic risk in PCOS remains incompletely explored. It is 
likely however, that non-alcoholic fatty liver disease (NAFLD), which is common in obese 
women with PCOS, contributes towards the metabolic dysfunction associated with PCOS 
(49).    
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Obstructive Sleep Apnoea in the development of PCOS 
Obstructive sleep apnoea (OSA) presents with recurrent episodes of complete or partial 
obstruction of the upper airway leading to intermittent hypoxia and chronic sleep loss 
(50). OSA is more common in men (51) and in patients with obesity (52).  
 
Patients with OSA have increased risk of insulin resistance, which is present even when 
adjusted for BMI (53). In this sense, OSA is similar to PCOS (20-22). Association of OSA with 
insulin resistance and metabolic derangement is complex, but changes in levels of cortisol, 
catecholamines and adipokines are likely to be contributory (54).  
OSA is commoner in women with PCOS than in BMI- and age-adjusted control women (55). 
A recent large longitudinal study showed that women with PCOS have a 2.26 higher risk of 
developing OSA compared to women without PCOS, irrespective of BMI or age (56). PCOS 
may increase risk of OSA through effects on the sex hormones progesterone and 
testosterone. In one study, progesterone reduced airway resistance by enhancing activity 
of the upper airway dilator muscle (57), thereby conferring protection from OSA in 
women. Furthermore, testosterone influences apnoeic threshold, with increased levels of 
testosterone resulting in breathing instability during sleep (58). Anovulation in PCOS 
typically associates with lowered levels of progesterone (2). This combined with increased 
levels of testosterone provides one sex hormone-related explanation for association of 
PCOS with OSA. The effects of testosterone on apnoeic threshold (58) may also provide 
one explanation (in addition to increased truncal fat around the neck) for the increased 
risk of developing OSA in men. Interestingly, visceral fat content (rather than total body 
fat) correlates with risk for development of OSA risk (59). As visceral fat content in women 
(regardless of PCOS status) increases commensurately with total fat content (45), this may 
contribute towards heightened risk of OSA in women with PCOS who gain weight.  
There are similarities between the metabolic derangements that typify OSA and PCOS 
(60). However, women with PCOS who also develop OSA have a metabolic double-
whammy, with enhanced insulin resistance and glucose intolerance, and greater risk of 
development of T2D and metabolic syndrome compared to women with PCOS without OSA, 
adjusted for BMI, ethnicity and age (60). Given the greater risk of development of OSA in 
women with PCOS, it is important that healthcare professionals are aware and institute 
regular OSA screening for women with PCOS. Treatment of OSA with continuous positive 
airways pressure (CPAP) therapy is effective at alleviating insulin resistance in women 
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with PCOS, and can at least partially reverse the associated metabolic derangements (61). 
Bariatric surgery is an excellent treatment option for OSA (resolution rate 85%) (62). 
Steroidogenesis and adipokines in the development of PCOS 
As alluded to above, insulin resistance and the associated hyperinsulinaemia is a driver for 
enhanced steroidogenesis in women with PCOS. Enhanced steroidogenesis (through co-
gonadotrophic effects within the ovary and direct effects within the adrenal (2)) results in 
hyperandrogenaemia and hyperandrogenic features including hirsutism that typify women 
with this condition. Weight gain and obesity in women with PCOS, through its effects on 
insulin resistance thereby drive enhanced steroidogenesis and hyperandrogenism. This 
provides an explanation for the close association between body weight and severity of the 
hyperandrogenic features of PCOS.   
 
Our own group has demonstrated association of PCOS with enhanced 5-alpha reductase 
activity in the largest study to date on urinary steroid profiles in women with PCOS 
(n=178) versus BMI-matched control women (n=100) (63). Furthermore, 5-alpha reductase 
activity correlated positively with increasing adiposity in both groups (63). The main 
effects of enhanced 5-alpha reductase activity on androgenicity in PCOS are two-fold: i) 
enhanced conversion of testosterone into 5-dihydroxytestosterone (a potent androgen), 
and; ii) enhanced conversion of cortisol into its breakdown products. As cortisol is broken 
down, negative feedback effect at the level of the pituitary diminishes, resulting in 
enhancement of hypothalamo-pituitary adrenal (HPA) axis activity and adrenal (including 
androgen) steroidogenesis production (63). 
Weight gain and obesity may also contribute to the clinical and biochemical expression of 
PCOS through effects on adipokine release (42). In a large meta-analysis on >3400 
subjects, it was demonstrated that serum adiponectin levels are lower in women with 
PCOS compared with BMI-adjusted control women, possibly contributing towards insulin 
resistance in PCOS (64). One of the steroidogenic effects of adiponectin is inhibition of 
androgen production from ovarian theca cells (65). It seems likely that enhancement of 
ovarian androgen production in women with PCOS is influenced, at least in part by 
suppressed levels of adiponectin (42). Consistent with this hypothesis is an observation of 
inverse correlation between levels of adiponectin and testosterone (and ovarian volume) 
in pubertal girls (n=56) with type 1 Diabetes Mellitus (66). The role of high molecular 
weight adiponectin in PCOS should be a focus for future research (67).  
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In addition to adiponectin, visfatin (implicated in metabolism, inflammation and insulin 
resistance (42, 68)) may also contribute towards metabolic dysfunction in PCOS (42), 
serum levels of visfatin being greater in women with PCOS than in control women (68-71). 
Retinol Binding Protein 4 may also play a role in mediating effects of weight gain and 
obesity on the development of PCOS (67, 72). However, another adipokine, adipocyte 
fatty acid-binding protein, whilst correlated with markers of obesity, does not appear to 
associate with metabolic or hyperandrogenic features of PCOS (73). 
 
Genetic factors in the development of PCOS 
Genetic factors contribute towards the development of both PCOS (74-76) and obesity 
(77). A recently reported large-scale genome-wide meta-analysis of PCOS showed evidence 
for shared genetic architecture between metabolic traits, including a causal link between 
obesity and PCOS (78). Given the epidemiological link between both conditions, it is 
important to consider a possible role for genetic variants.   
 
FTO (fat mass and obesity-associated gene) was the first gene identified from a genome-
wide association study (GWAS) to have a robust effect on susceptibility for development of 
common polygenic obesity (79, 80). Variants within FTO influence fat mass (per-allele 
difference in BMI 0.36kgm-2) (79). In a UK-based study on 463 UK PCOS cases and >1,300 
UK female controls, our own group demonstrated a significant association between a 
variant within FTO (rs9939609 single nucleotide polypeptide) and PCOS-status (OR per 
minor allele copy 1.30), attenuated by adjustment for BMI between cases and controls 
(81). These data showed for the first time a genetic corroboration for a mechanistic link 
between PCOS and obesity (81). Subsequent studies in diverse populations have confirmed 
association between variants in FTO and PCOS status (82-84). Based on the data outlined 
here, it seems likely that genetic factors that include FTO variants, contribute towards 
development of PCOS through effects on increased fat mass and weight gain. Such genetic 
effects on fat mass are likely to provide an explanation for at least some of the 
heritability of PCOS.  
 
PCOS as a risk factor for the development of obesity 
Much epidemiological data confirm a close association between obesity and PCOS (2, 17). 
As outlined earlier, much evidence confirms a clear effect of weight gain on development 
of PCOS, and weight loss on its alleviation, mediated for example through effects on 
insulin sensitivity (2). Furthermore, data from NFBC 1966 show association between early 
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adiposity rebound during childhood and diagnosis of PCOS and obesity in adulthood (85). 
However, PCOS is a complex condition, and it is likely that its relationship with obesity is 
also complex. It is important to consider possible mechanisms whereby PCOS may 
contribute towards further weight gain, or hamper successful attempts at weight loss and 
maintenance of body weight through lifestyle means in women with this condition, 
outlined in this section.   
 
Energy Expenditure as a contributor to weight gain in PCOS 
Changes in energy expenditure over prolonged periods could influence body weight. It is 
important to consider therefore whether PCOS is associated with changes in any aspect of 
metabolism. Robinson and colleagues performed continuous indirect calorimetry in 14 
women with PCOS and 14 controls in a cross-sectional design (86). Compared with 
controls, postprandial thermogenesis was significantly lower in women with PCOS, and 
that the difference between groups was more marked for obese women with PCOS (a 
difference of 41.1kJ). Furthermore, the level of insulin resistance correlated with the 
reduction in postprandial thermogenesis in the PCOS group (86). Interestingly, resting 
energy expenditure was similar between groups in this study (86). More recently, 
measurement of resting metabolic rate using a SenseWear Armband in 109 women with 
PCOS versus 31 control women (87) showed that resting metabolic rate was equivalent 
between groups (87).  
 
There is a lack of clear data in the literature to enable any meaningful conclusions 
regarding potential effects of PCOS on energy expenditure. Furthermore, even if PCOS is 
truly associated with diminished energy expenditure (either postprandial and/or resting 
components), this would not necessarily result in weight-gain over time: central control of 
the components of metabolism and interlinks between appetite, gut peptides and nutrient 
supply is highly complex and incompletely understood. Postprandial thermogenesis 
accounts for a relatively small proportion of overall metabolism. It seems unlikely that 
modest changes in postprandial thermogenesis would contribute towards clinically 
meaningful weight gain in PCOS. Without long-term and more complete data, and a better 
understanding of the complexity of body weight regulation, the data outlined above 
remain interesting observations. Potential implications for body weight regulation however 
are uncertain. 
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Androgen-mediated lipolysis as a contributor towards weight gain in PCOS 
PCOS may associate with abnormalities in lipolytic functioning of adipocytes (2). In one 
study, catecholamine-induced lipolysis within isolated visceral adipocytes was increased 
two-fold in non-obese women with PCOS compared with BMI-matched control women (88), 
possibly mediated by changes in function of the post-receptor Protein Kinase A – Hormone 
Sensitive Lipase complex (2, 88). Furthermore, in normal men and women, testosterone 
facilitates release of non-esterified fatty acids from visceral adipocytes in vivo (89). Most 
studies of androgen effects on the adipocyte have shown a stimulatory effect on lipolysis, 
and impaired adipocyte differentiation, insulin signalling and generation of adipokines 
(90). However, there is tight control of exposure of adipocytes to androgens through key 
isoenzymes. Within abdominal subcutaneous adipose tissue, androgen inactivation usually 
predominates (90).   
 
The effects of androgens on lipolysis and adipocyte function in women with PCOS, the 
site-specificity and possible mediating effects of fat mass are incompletely understood, 
and worthy of further research focus. It remains possible that androgen-mediated 
enhanced visceral lipolysis contributes towards metabolic dysfunction in PCOS. However, 
based on current data it is premature to hypothesize a role for changes in subcutaneous 
adipocyte lipolysis as a factor that contributes towards weight gain in some women with 
PCOS.   
 
Mental health problems as a contributor to weight gain in PCOS  
Implementation of effective lifestyle strategies to achieve and maintain weight-loss and 
mitigate against ongoing weight-gain, usually requires focus, drive and commitment. Any 
mental or emotional health problem can potentially hinder such attempts at lifestyle 
implementations (including dietary changes and engagement in physical activity). There 
are complex interactions between obesity and mental health problems that often establish 
during childhood (91). It is likely that interlinks between obesity and mental health 
problems (including poor emotional health and self-esteem) are complex and multi-
directional. 
 
In obese women with PCOS, there are also often features like hirsutism, menstrual 
irregularities and fertility problems that amalgamate with the already complex interlinks 
between obesity and mental and emotional functioning. Unsurprisingly, women with PCOS 
are susceptible to mental health problems. In one cross-sectional and self-reported study 
on 177 women with PCOS and 109 healthy controls, scores for anxiety, depression and 
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negative body image were significantly higher in the women with PCOS (92). Body image 
and self-worth were predictors of anxiety and depression (regardless of PCOS status), and 
time taken to diagnose PCOS was associated with poor psychological functioning (92). In 
another cross-sectional study on 50 patients with PCOS and 41 health controls, women 
with PCOS had significantly higher depression and anxiety scores compared with the 
controls (93). Interestingly however, temperament and character were equivalent 
between PCOS and control groups (93). In a further study that focused on adolescent girls 
aged 13-18 years and diagnosed with PCOS, there was very little perceived self-control 
(including menstrual irregularities and threat of infertility). Perception of poor self-control 
was a predictor for depression (94). 
 
Data from the NFBC 1966 show that at ages 31 and 46 years, compared with controls, 
women with PCOS have increased anxiety and/or depression symptoms (95). It is 
reasonable to hypothesize that depression and anxiety (and perceived diminishment in 
self-control) at different ages would all potentially hinder attempts at lifestyle 
implementation and successful weight-loss. This includes engagement in physical activity 
(as outlined in the next section), but would also extend to other aspects of healthy living 
including diet and sleep sufficiency for example. The data outlined stem from cross-
sectional (association) studies. Therefore, inference of causality is not possible. It is likely 
though that the clinical manifestation of PCOS (with frequent co-occurrence of obesity) 
and mental/emotional problems have complex and multi-directional interlinks and vary 
between individuals. Whilst pre-existent mental health problems may contribute towards 
weight-gain and the manifestation of PCOS in those who are genetically-predisposed (77), 
it seems likely also that features of PCOS, including the perceived lack of self-control 
especially at the vulnerable age of adolescence (94), would predispose to new 
development or worsening of pre-existing mental and emotional problems. A vicious cycle 
may ensue in which worsening features of PCOS beget heightened anxiety, depression, 
body image and perceived lack of self-control that in turn hinders attempts at 
implementing lifestyle measures to facilitate weight-loss. Therefore in at least some 
women, PCOS may lead to further weight-gain (or at least dampen attempts at successful 
weight-loss), mediated indirectly through associated mental and emotional problems.  
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Physical inactivity as a contributor to weight gain in PCOS  
Physical inactivity is an important contributor to most chronic disease (96). The benefits 
of physical activity for the populace are legion, and include interesting cross talk between 
muscle and brain (97). As in obesity management in general, maintenance of physical 
activity and exercise forms a key aspect of lifestyle advice for women with PCOS (2). 
Benefits include promotion of weight-loss (2); fasting insulin levels and waist 
circumference (98); free androgen index (99), and; blood pressure, lipid profile, glucose 
levels and reduction in fat mass (100). It is important to consider whether PCOS may 
contribute towards weight-gain and obesity (or at least resistance to effective weight-
loss), through effects of the condition on ability to engage in physical activity, mediated 
by possible PCOS-related emotional and physical factors. It is important to highlight that 
the factors discussed below may also apply to the general obese populace regardless of 
PCOS status, given the complex association between obesity and emotional and physical 
functioning (101, 102). 
 
Emotional factors implicated in physical inactivity in PCOS: Despite a lack of well-
controlled studies reported in the literature on physical activity in PCOS (103), one study 
reported by Banting and colleagues compared self-reported measures of physical activity 
and depression and anxiety scores in women with and without PCOS (104). Compared with 
controls, women with PCOS experienced more barriers to physical activity including 
emotional factors like lack of confidence and fear of injury, and physical limitations (104). 
Encouragingly however, physically active women (regardless of PCOS status) experienced 
less severe depression than that in their inactive counterparts (104). Other studies support 
the benefits of physical activity on mental health in PCOS. These include beneficial effects 
of brisk-walking over 6-months on body image distress score (105), and beneficial effects 
of enhanced exercise as part of lifestyle modification on improvements on self-esteem, 
depression and anxiety (106).  
 
Physical factors implicated in physical inactivity in PCOS: There is some controversy in 
the literature regarding physical cardiorespiratory fitness in women with PCOS. One study 
demonstrated that VO2 max is impaired in young overweight women with PCOS (107), 
whilst another study showed equivalence of physical fitness between women with PCOS 
and age- and BMI-matched controls (108). Differences in insulin sensitivity between 
subjects in each study may have contributed towards some of the discrepancies regarding 
physical fitness in PCOS between studies (103). No apparent differences exist between 
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women with PCOS and healthy controls regarding muscle strength (108) and levels of free-
living physical activity (109). 
 
To summarize this section, evidence to support a direct effect of PCOS on physical ability 
to engage in physical activity (including muscle strength and fitness) appears scant. 
However, there is clear evidence to support the notion that PCOS may have a negative 
impact on engagement in physical activity, mediated indirectly through emotional 
barriers. Although long-term prospective studies are not available, it seems reasonable to 
hypothesize that such disengagement in physical activity would eventually contribute 
towards weight-gain and hamper efforts to lose weight. Given the huge benefits of 
physical activity (including improvements in mental and emotional health), it is important 
to manage any emotional barriers to its effective execution proactively, sensitively and in 
a timely manner.   
 
Novel management strategies for obesity and PCOS 
Although many therapies exist for management of PCOS, most of these target 
manifestations of PCOS rather than underlying causal mechanisms. Effective weight-loss 
implementation remains the most effective and promising management strategy for 
women with PCOS. However, this presents a problem: weight-loss maintenance through 
lifestyle implementation is challenging, and has a high failure rate (110). Whilst bariatric 
surgery represents an excellent alternative strategy to lifestyle implementation for 
effective and long-term weight-loss (111), surgical management strategies for obesity 
associated with PCOS will never be scalable to a population level. Our current therapeutic 
armamentarium for obesity in the UK is diminutive. Novel management strategies for PCOS 
in the context of obesity should therefore focus on effective means of maintaining weight-
loss over the longer term on a population level. 
 
Appetite enhancement is a key driver of weight-regain following weight-loss, and one that 
persists for at least a year (112). It is logical to develop future therapies that suppress 
appetite enhancement following initial weight loss. Data on appetite suppressant effects 
of key gut peptides are promising, and promote certain gut peptides such as Peptide 
tyrosine tyrosine (PYY) as potential future therapies to complement lifestyle strategies for 
weight-maintenance following initial weight-loss (113). However, these gut peptide 
therapies are likely to be expensive, and will likely require injectable administration. In 
addition to appetite suppression, therapies to improve hyperlipidaemia may impact 
beneficially on hyperandrogenaemia in PCOS (114). 
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An alternate novel strategy for weight loss, one that is entirely scalable on a population 
level and which everyone can implement, is the application of mindfulness to lifestyle 
strategies. Our own group demonstrated significant improvements in dietary-induced 
weight-loss and healthy eating-related behaviours amongst obese patients attending group 
sessions in the context of a UK-based tier 3 obesity service (115). It is reasonable to 
hypothesize application of mindfulness techniques to other aspects of lifestyle change 
including physical activity, to facilitate successful adoption of lifestyle change in obese 
women with PCOS. We envision that self-taught mindfulness techniques, administered 
through appropriate and wide-reaching infrastructure and adopted by the populace at 
scale, could represent a novel and effective strategy to promote maintenance of body 
weight following initial weight loss in obese women with PCOS. In this way, mindfulness 
approaches could complement changes in diet and physical activity in obese women with 
PCOS. This should be a focus of future research.  
Although not a novel strategy, it is worth considering the benefits of physical exercise in 
PCOS (independent of any weight-loss) in more detail. Aerobic exercise can improve 
reproductive function in women with PCOS, including normalization of menstrual cyclicity 
(98, 99) and ovulation rates (99). In fact, exercise (possibly through improvements in 
insulin sensitivity) appears to result in improvements in menstrual cyclicity and/or 
ovulation in around 50% of women with PCOS (103). It is worth highlighting though that 
excessive exercise (>60 minutes per day) can increase risk of anovulation, whereas 
exercise duration of 30-60 minutes per day reduces the risk of anovulatory infertility 
(116). Therefore, promotion of moderate (and avoidance of excessive) exercise are 
important health messages for women with PCOS. 
 
Conclusions and future directions 
It is widely accepted based on current evidence, that weight-gain and obesity are 
important risk factors for the clinical and biochemical manifestations of PCOS in those 
women who are genetically predisposed (117). The multiple mechanisms mediating this 
process are complex. However, the association between obesity and PCOS is more complex 
than a simple cause-and-effect process, and likely includes complicated interlinks 
between multiple factors. As outlined, it seems likely that in at least some obese women 
with PCOS, development of PCOS through indirect mechanisms (including depression and 
perceived lack of self-control and increased distress), may hamper ongoing attempts at 
lifestyle change and therefore effective weight-loss. Indeed, such factors may even 
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promote further weight-gain, thereby setting in play a vicious circle that can be difficult 
to vanquish. 
 
As healthcare professionals, we are all likely to encounter women with PCOS given its 
prevalence and close association with obesity. Given the future projection of the obesity 
epidemic, it is likely that the overall prevalence of PCOS will continue to increase. 
Furthermore, PCOS often becomes manifest during adolescence, a vulnerable time of life. 
It is incumbent upon all healthcare professionals to recognise the plight of women and 
girls with PCOS, and the complexity of its pathogenesis. We need to manage these 
patients with sensitivity and empathy, whilst also pursuing a proactive approach, 
particularly regarding presence and emergence of mental and emotional health problems. 
This is particularly important given the stigmatization of mental ill health and obesity 
within our society. We need to adopt a holistic approach to weight management in PCOS: 
one that addresses not just lifestyle change but any potential mental and emotional 
barriers to its effective implementation. Only then can we hope to convert the typified 
vicious circle of weight-gain and worsened features of PCOS, into a liberated virtuous 
cycle of effective weight-loss and eventual freedom from the shackles of PCOS. 
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Figure 1: Summary of mechanisms linking obesity with PCOS 
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